The European Medicines Agency has recommended expanding Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvytki (ciltacabtagene autoleucel) for use as an earlier treatment in patients with relapsed or refractory multiple myeloma, Legend announced on Friday.
Roche on Sunday released results from the first stage of the Phase III OUtMATCH study, demonstrating that its asthma drug Xolair (omalizumab) can significantly reduce severe allergic reactions in patients with several food allergies.
British drugmaker GSK said on Monday its oral drug to treat gonorrhea met the main goal of non-inferiority, compared to an existing combination treatment, in a late-stage trial.
Vifor Pharma and partner Travere Therapeutics on Friday won an endorsement for approval from the European Union’s drug regulator for their drug Filspari, part of an industry race to treat a rare, serious kidney condition known as IgAN.
Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry’s embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found.
Indian pharma companies have started developing their own versions of Novo Nordisk’s top-selling weight-loss medicine Wegovy (semaglutide), hoping for a piece of the multibillion-dollar obesity market.
Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round, which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376.
San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).
Pfizer CEO Albert Bourla and Sanofi CEO Paul Hudson will serve alongside O’Day, becoming PhRMA’s board chair-elect and treasurer, respectively.
The profit was helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot.
